United States
Content provided by Bausch + Lomb Medical Affairs.
Content provided by Bausch + Lomb Medical Affairs.
Dedicated to dry eye disease and ocular surface health, bringing together clinicians and researchers across Europe. Bausch + Lomb was present through scientific abstracts and sponsored educational content. Submitted publications highlighted Artelac® Complete, Artelac® 4S, Artelac® Rebalance and Ectoine. Additional data addressed artificial tear performance and dry eye symptom relief.
AIM: To document real-world patient characteristics, utilisation patterns, and clinical outcomes with Artelac Ultra 4S (AS) lubricating eye drops (sodium hyaluronate, trehalose, fucoidan, D-panthenol) in patients with dry eye disease (DED).
METHODS: This retrospective, multi-country, cross-sectional case review study included currently licensed ophthalmologists with ≥3 years' experience treating patients with DED, and ≥1 years' experience with ≥1 of the DED study drops. Healthcare providers (HCPs) provided a deidentified, retrospective convenience sample of lubricating eye drop cases using a standardised case report form. The protocol received central institutional review board exemption. Here, we report the sub-analysis of patients treated with AS.
RESULTS: This interim sub-analysis included five cases from one ophthalmologist unless otherwise specified. Patients had a mean±SE age of 47.4±7.9 years, were all female, were not contact lens users, and 40% had ocular comorbidities (including previous cataract surgery and glaucoma). Two patients received prior DED treatment (hyaluronic acid-based drops), which were not considered effective enough in both patients. All patients used AS lubricating eye drops QID. At a mean±SE follow-up of 37.2±2.9 weeks, improvements from baseline were reported in mean tear break-up time (TBUT) and Schirmer test. In all cases, the HCP reported improvements in the signs, symptoms, and patient-reported symptoms of DED. In 4/5 cases, clinical effectiveness was rated as "very effective" (one case was ranked as "somewhat effective"), with no tolerability concerns reported. Additionally, no treatment-related adverse events related to the study drug were reported.
CONCLUSIONS: In this real-world retrospective case review, most HCPs considered AS to be very clinically effective, with patients experiencing decreased signs and symptoms, with no tolerability concerns and no adverse events reported.
AIM: Traditionally, dry eye relief has been provided by water-based artificial tears (ATs), but ATs with lipid components have emerged to provide lubrication while decreasing tear evaporation. This study compared two preservative-free ATs with sodium hyaluronate (SH) in patients with moderate-to-severe dry eye disease: a multicomponent 0.24% SH eye drop with carbomer and triglycerides as lipids (SH-CB-TG), and an aqueous-based comparator (C-SH) with 0.18% SH.
METHODS: In this multicentre, investigator-masked, noninferiority study, patients were randomised to SH-CB-TG or C-SH, administered 3–6 times daily for 3 months. The primary endpoint was change from Baseline in the ocular surface fluorescein staining (OSFS) score (0–15 per the Oxford scheme) at Day 28 in the per-protocol population. Secondary endpoints included OSFS at 3 months, tear film break-up time, dry eye symptoms, quality-of-life questionnaire (OSD-QoL) and frequency of AT instillation.
RESULTS: The primary non-inferiority endpoint (OSFS) was met, together with endpoints on symptoms. At baseline, mean (SD) global dry eye symptom scores (0–28) were 11.1 (±3.8) in the SH-CB-TG group and 9.2 (±3.8) in the C-SH group. By Day 28, scores had decreased by 3.9 (±0.5) and 2.1 (±0.5), respectively, representing a significant difference between treatment groups (-1.8, 95% CI:-3.2, -0.3; P=0.0176). At the end of three months, the treatment difference had increased to (-2.4, 95% CI:-3.8, -1.0; P=0.0010) and QoL questionnaires demonstrated a significant advantage in the SH-CB-TG group (OSD Global question, adjusted treatment difference, 8.2, 95% CI:0.8, 15.6; P=0.0306). OSD-QoL assessments showed improvement of 6 dimensions in the SH-CB-TG group and 5 dimensions in the C-SH group. There was a significant difference in 3 dimensions in favour of the SH-CB-TG group: Daily activities, Handicap and work difficulties and Acknowledgement of the disease.
CONCLUSION: The multicomponent, lipid-containing SH-CB-TG may offer additional advantages in ameliorating symptoms of dry eye.
AIM: To explore healthcare providers' (HCPs) real-world experience with Artelac lubricating eye drops in patients with dry eye disease (DED).
METHODS: This retrospective, multi-country, cross-sectional survey study included currently licensed ophthalmologists with ≥3 years' experience treating patients with DED, and ≥1 year's experience with the study drops. HCPs completed a user experience survey documenting clinical practice characteristics, lubricating drop utilisation patterns in DED, real-world clinical outcomes, and HCP satisfaction with the study drops. The protocol received central IRB exemption.
RESULTS: This interim analysis included nine HCPs from Turkey (n=3), Spain (n=2), Dubai (n=1), Germany (n=1), Poland (n=1), and Italy (n=1). Most were from a university public hospital with a teaching/research department (5/9) and/or a private clinic (5/9) and were from a range of specialties (including ocular surface disease, DED, corneal, or cataract specialists). Each HCP completed the survey based on their experience with one specific Artelac formulation: Artelac Complete (n=5), Artelac Ultra 4S (n=3), and Artelac Nightime Gel (n=1). All HCPs recommend the study drops to patients with all severities of DED, to patients pre- and post-ocular surgery, and to patients with DED induced and/or exacerbated by contact lenses. In the last year, the drops were most frequently recommended in evaporative deficiency (~mean±SE: 43%±9.2%) or both evaporative and aqueous deficiency DED (~mean±SE: 44%±8.7%) of moderate severity (~mean±SE: 43%±3.7%). Ocular comorbidities were documented in an ~mean±SE 45%±5.9% of patients, including cataracts in 29%±4.7% and glaucoma in 19%±3.3%. An ~mean±SE 41%±8.4% of patients self-reported symptom resolution after their first course of treatment with the study drops. Most HCPs reported high levels of satisfaction with the study drops, overall, and in improving individual signs and symptoms.
CONCLUSIONS: These findings provide important insights into lubricating drop utilisation patterns in DED treatment. HCPs reported high levels of satisfaction with Artelac, overall, and in improving individual signs and symptoms.
Get Support
Contact UsContact a
Representative
Submit a
Medical Inquiry
The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.
